Back to Search Start Over

Association of sclerostin with cardiovascular events and mortality in dialysis patients

Authors :
Yun Zou
Min Yang
Jiao Wang
Li Cui
Zhenxing Jiang
Jiule Ding
Min Li
Hua Zhou
Source :
Renal Failure, Vol 42, Iss 1, Pp 282-288 (2020)
Publication Year :
2020
Publisher :
Taylor & Francis Group, 2020.

Abstract

Introduction Sclerostin has been reported to be a novel biomarker associated with the bone-vascular axis. In this study, we determined the relationships between serum sclerostin and all-cause mortality, the prevalence of cardiovascular events (CVEs), and coronary artery calcifications (CACs) in dialysis patients. Methods A total of 165 dialysis patients (84 hemodialysis [HD] and 81 peritoneal dialysis [PD]) were enrolled in this study. We performed multivariable linear regression analysis to test the relationships between serum sclerostin levels and demographics and clinical parameters. We also performed Cox proportional hazard regression analysis to determine independent predictors of overall survival and CVEs. Results The median serum sclerostin level was 250.9 pg/mL in dialysis patients. Kaplan–Meier analysis showed that both overall and CVE-free survival rates were significantly lower in the high serum sclerostin group (serum sclerostin level >250.9 pg/mL) compared to the low serum sclerostin group (serum sclerostin level ≤250.9 pg/mL) in patients with PD (p 0.05). Conclusions A low serum sclerostin was associated with better overall survival and lower prevalence of CVEs in patients with PD, but had no relationships in patients with HD. We found that serum sclerostin level was not correlated with CACs in either patients with HD or PD.

Details

Language :
English
ISSN :
0886022X and 15256049
Volume :
42
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Renal Failure
Publication Type :
Academic Journal
Accession number :
edsdoj.91fcce17e749718212cd49b10a3aad
Document Type :
article
Full Text :
https://doi.org/10.1080/0886022X.2020.1741386